Synthesis and structure-activity relationships of novel IKK-β inhibitors. Part 3: Orally active anti-inflammatory agents

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 15, 2004, Pages 4019-4022

  Murata, Toshiki ^a   Shimada, Mitsuyuki ^a   Sakakibara, Sachiko ^a   Yoshino, Takashi ^a   Masuda, Tsutomu ^a   Shintani, Takuya ^a   Sato, Hiroki ^a   Koriyama, Yuji ^a   Fukushima, Keiko ^a   Nunami, Noriko ^a   Yamauchi, Megumi ^a   Fuchikami, Kinji ^a   Komura, Hiroshi ^a   Watanabe, Akihiko ^a   Ziegelbauer, Karl B ^a   Bacon, Kevin B ^a   Lowinger, Timothy B ^a  

^a BAYER YAKUHIN LTD   (Japan)

Author keywords

IKK ; Kinase inhibitor; NF B

Indexed keywords

ANTIINFLAMMATORY AGENT; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; EDEMA; ENZYME INHIBITION; EVALUATION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; EDEMA; HUMANS; I-KAPPA B KINASE; KINETICS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3042642760     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.05.041     Document Type: Article

References (12)

1. Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L., Jian, Wu Li, Young D.B., Barbosa M., Mann M., Manning A., Rao A. Science. 278:1997;860
2. Woronicz J.D., Gao X., Cao Z., Rothe M., Goeddel D.V. Science. 278:1997;866
3. Zandi E., Rothwarf D.M., Delhase M., Hayakawa M., Karin M. Cell. 91:1997;243
4. For recent reviews, see: Ghosh S., Karin M. Cell. 109(Suppl: S81):2002
5. Senftleben U., Karin M. Crit. Care Med. 30:2002;S18
6. Murata T., Shimada M., Sakakibara S., Yoshino T., Kadono H., Masuda T., Shimazaki M., Shintani T., Fuchikami K., Sakai K., Inbe H., Takeshita K., Niki T., Umeda M., Bacon K.B., Ziegelbauer K.B., Lowinger T.B. Bioorg. Med. Chem. Lett. 13:2003;913
7. Murata, T.; Shimada, M.; Kadono, H.; Sakakibara, S.; Yoshino, T.; Masuda, T.; Shimazaki, M.; Shintani, T.; Fuchikami, K.; Bacon, K. B.; Ziegelbauer, K. B.; Lowinger, T. B. Bioorg. Med. Chem. Lett. 2004, 14, preceding paper in this issue. doi:10.1016/j.bmcl.2004.05.040
8. For further details of the syntheses, see: Murata, T.; Umeda, M.; Sakakibara, S.; Yoshino, T.; Sato, H.; Masuda, T.; Koriyama, Y.; Shimada, M.; Shintani, T.; Kadono, H.; Ziegelbauer, K. B.; Fuchikami, K.; Komura, H.; Lowinger, T. B. WO 0224679, 2002; Chem. Abstr. 2002, 136, 279345
9. D'Acquisto F., Iuvone T., Rombola L., Sautebin L., Di Rosa M., Carnuccio R. FEBS Lett. 418:1997;175
10. Camandola S., Leonarduzzi G., Musso T., Varesio L., Carini R., Scavazza A., Chiarpotto E., Baeuerle P.A., Poli G. Biochem. Biophys. Res. Commun. 229:1996;643
11. Puignero V., Queralt J. Inflammation. 21:1997;431
12. In vivo arachidonic acid-induced ear edema in mice: ear edema was induced by topical application of arachidonic acid (500 μg/ear). Compound 4j, dexamethasone and vehicle (10% cremophor in saline) were given po 60 min before the arachidonic acid application. Ear thickness was measured at 0, 1, 3 and 6 h after the arachidonic acid application. Each column indicates the mean and SEM of 5 mice